Brachytherapy

Papers
(The TQCC of Brachytherapy is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Editorial Board37
Editorial Board31
Biochemical outcome of prostate cancer patients treated with hypofractionated external radiation and a single high-dose-rate brachytherapy boost29
PO024926
PO032419
PO042516
MPP02 Presentation Time: 4:09 PM14
PPP02 Presentation Time: 10:39 AM14
PO022713
BP08 Presentation Time: 5:03 PM13
PPP03 Presentation Time: 10:48 AM12
PO041712
BP02 Presentation Time: 4:09 PM12
3D-printed radiopaque episcleral plaques with radioactive collimating cavities for enhanced dose delivery in brachytherapy12
Thursday, July 11, 20249:00 AM - 10:00 AMGPP01 Presentation Time: 9:00 AM12
Thursday, July 11, 20244:00 PM - 5:00 PM MPP01 Presentation Time: 4:00 PM11
PSOR12  Presentation Time: 5:25 PM11
PHSOR06 Presentation Time: 9:25 AM11
Effects of pain management using nonsteroidal anti-inflammatory drug suppositories during brachytherapy for cervical cancer: A single-center prospective observational study10
PSOR8  Presentation Time: 12:05 PM10
PSOR03  Presentation Time: 12:10 PM10
After ASCENDE-RT: Biochemical and survival outcomes following combined external beam radiotherapy and low-dose-rate brachytherapy for high-risk and unfavourable intermediate-risk prostate cancer, a po10
PO4710
PO3510
PO9310
Low-Dose-Rate versus High-Dose-Rate intracavitary brachytherapy in cervical cancer - Final Results of a Phase III randomized trial9
Factors associated with late local failure and its influence on survival in men undergoing prostate brachytherapy9
A new way to visualize prostate brachytherapy needles using ultrasound color Doppler and needle surface modifications9
Patient-controlled epidural analgesia, patient-controlled intravenous analgesia, and conventional intravenous opioids for gynecologic interstitial brachytherapy: A single-center retrospective study9
Prospective randomized trial of email and/or telephone reminders to enhance vaginal dilator compliance in patients undergoing brachytherapy for gynecologic malignancies9
PO208
GSOR04  Presentation Time: 12:15 PM8
PO218
Clinical outcomes of adaptive intracavitary and interstitial brachytherapy technique in locally advanced cervical cancer: A real-world data8
PSOR02  Presentation Time: 4:35 PM7
Sunday, June 19, 202211:30 AM - 12:30 PMGSOR13  Presentation Time: 11:30 AM7
PHSOR04  Presentation Time: 12:45 PM7
Masthead7
PL02  Presentation Time: 1:45 PM7
PO107
PHSOR05  Presentation Time: 12:50 PM7
PP02  Presentation Time: 9:10 AM7
PO46  Presentation Time: 4:45 PM7
MSPP03  Presentation Time: 4:20 PM7
GSOR14  Presentation Time: 11:35 AM7
Table of Contents7
High-dose-rate brachytherapy for airway malignancy a single institution experience6
MSOR12 Presentation Time: 8:55 AM6
PO02346
PO04216
Cs-131 prostate brachytherapy boost and effect of hydrogel rectal spacer on long-term patient-reported rectal bleeding and bowel quality of life6
PP05  Presentation Time: 5:06 PM6
Determination of the optimal time for planning SAVI brachytherapy for APBI6
Radical trachelectomy and adjuvant vaginal brachytherapy to preserve fertility in pediatric cervical adenocarcinoma6
Impact of MRI-based planning in transperineal interstitial brachytherapy for locally advanced cervix tumors: Clinical, dosimetric and toxicity outcomes6
MSOR11 Presentation Time: 8:50 AM6
Novel portable apparatus for outpatient high-dose-rate (HDR) brachytherapy in penile cancer6
The case for risk-stratified IORT for early breast cancer6
Table of Contents6
Comparison of novel shielded nasopharynx applicator designs for intracavitary brachytherapy6
Masthead6
PL02 Presentation Time: 1:45 PM6
Is hemi-gland focal LDR brachytherapy as effective as whole-gland treatment for unilateral prostate cancer?6
Exclusive Ru-106 brachytherapy for the management of a recurrent corneo: Conjunctival squamous cell carcinoma6
Increasing global access to brachytherapy: The ABS 300 in 10 initiative and ongoing international efforts5
The association of vagina equivalent dose in 2Gy fraction (EQD2) to late vagina toxicity in patients of cervical cancer treated with WPRT plus IGABT5
Targeting the GTV in medically inoperable endometrial cancer using brachytherapy5
US-guided versus US-assisted tandem insertion for cervical cancer: A nomenclature proposal5
PO04245
PO01095
A primer on time-driven activity-based costing in brachytherapy5
PO195
Impact of the COVID-19 pandemic on brachytherapy and cancer patient outcomes: A systematic review5
I-125 eye-plaque seed economics: To re-use or to not re-use? A single institutional cost savings analysis of re-using I-125 radioactive seeds for eye—Plaque brachytherapy5
Improving efficiency and reducing costs of MRI-Guided prostate brachytherapy using Time-Driven Activity-Based costing5
PO02415
PO02425
Partial breast irradiation: An updated consensus statement from the American brachytherapy society5
On the value of an EM tracking quality assurance system for pretreatment verification of needle digitization accuracy in ultrasound-based prostate HDR brachytherapy5
US-guided EM tracked system for HDR brachytherapy: A first in-men randomized study for whole prostate treatment5
Brachytherapy for favorable prognostic prostate cancer in men up to 60 years of age: Long term follow-up5
PSOR02 Presentation Time: 11:35 AM5
Skin Posters PO07015
PO01195
PP04  Presentation Time: 9:47 AM4
Intraoperative radiation and electronic brachytherapy in Brachytherapy: A look back and forward4
PO1144
The American Brachytherapy Society and Indian Brachytherapy Society consensus statement for the establishment of high-dose-rate brachytherapy programs for gynecological malignancies in low- and middle4
Quantifying risk using FMEA: An alternate approach to AAPM TG-100 for scoring failures and evaluating clinical workflow4
PO914
PO40  Presentation Time: 4:45 PM4
PO524
PP05  Presentation Time: 11:36 AM4
PO534
Characterization of combined intracavitary/interstitial brachytherapy including oblique needles in locally advanced cervix cancer4
PO154
PHSOR06  Presentation Time: 12:55 PM4
Thursday, June 22, 20233:30 PM - 4:30 PMPP01  Presentation Time: 3:30 PM4
Multipurpose ultrasound-based prostate phantom for use in interstitial brachytherapy4
PO33  Presentation Time: 10:30 AM4
Author Index of the Abstracts of the 2022 American Brachytherapy Society Annual Meeting4
PO864
The NorCal brachytherapy waste audit: A simple, validated, toolkit for clinician led waste reduction4
PP02  Presentation Time: 10:09 AM4
Toward 3D-TRUS image-guided interstitial brachytherapy for cervical cancer4
Detection of failure patterns using advanced imaging in patients with biochemical recurrence following low-dose-rate brachytherapy for prostate cancer4
Are outcomes of locally advanced cervical cancer associated with prebrachytherapy hemoglobin values and transfusion practice? An observational study comparing two large academic centres with divergent4
Prospective validation of a machine learning model for applicator and hybrid interstitial needle selection in high-dose-rate (HDR) cervical brachytherapy3
Table of Contents3
Masthead3
Dosimetric evaluation of iodine-125 brachytherapy for brain tumors using MR guidance combined with a three-dimensional non co-planar template3
MSPP05  Presentation Time: 4:40 PM3
PO123
Four-fraction ultra-accelerated minimal breast irradiation in early breast cancer: The initial feasibility results of an institutional experience3
PP02  Presentation Time: 8:29 AM3
Demographic and clinical factors associated with variations in opioid administration using conscious sedation during HDR brachytherapy for cervical cancer3
GSOR09 Presentation Time: 12:10 PM3
PO03203
The influence of time and implants in high-dose rate image-guided adaptive brachytherapy for locally advanced cervical cancer3
PPP05 Presentation Time: 11:06 AM3
PO04083
Uncertainty in magnetic resonance imaging-based prostate postimplant dosimetry: Results of a 10-person human observer study, and comparisons with automatic postimplant dosimetry3
MSS11  Presentation Time: 4:35 PM3
Dosimetric evaluation of a novel modular cell irradiation platform for multi-modality in vitro studies including high dose rate brachytherapy3
MSOR9 Presentation Time: 5:40 PM3
PHSOR08  Presentation Time: 1:05 PM3
GYN Posters PO013
Targeting prostate lesions on multiparametric MRI with HDR brachytherapy: Optimal planning margins determined using whole-mount digital histology3
A general framework to develop a radiomic fingerprint for progression-free survival in cervical cancer3
MSOR11 Presentation Time: 5:50 PM3
PO02613
PSOR7  Presentation Time: 12:00 PM3
PO02583
GSOR10 Presentation Time: 12:15 PM3
Patient-specific cylinder templates for hybrid interstitial vaginal brachytherapy: Feasibility of automated 3-D design, 3D printing, and dosimetric outlook3
PO493
PO27  Presentation Time: 7:40 AM3
PO323
Inter-fractional variation of markers and applicators in single-implant high-dose-rate interstitial brachytherapy for gynecologic malignancies3
PP04  Presentation Time: 11:27 AM3
Laminaria tent insertion in preplanning MRI for CT-based cervical cancer brachytherapy3
PO02203
Thursday, July 11, 20244:00 PM - 5:30 PM BP01 Presentation Time: 4:00 PM3
PO01103
PSOR3  Presentation Time: 11:40 AM3
PO03113
PO04282
Editorial Board2
PO03142
What is appropriate target delineation for MRI-based brachytherapy for medically inoperable endometrial cancer?2
PO822
PO102
Percutaneous interstitial brachytherapy ablation for targeting oligometastatic gynecologic cancers2
Table of Contents2
MSS10  Presentation Time: 4:30 PM2
PO042
PO02442
Feasibility of balloon rectal spacer implantation in HDR and LDR brachytherapy for prostate cancer treatment2
PSOR05 Presentation Time: 11:50 AM2
Definitive treatment for primary urethral cancer: A single institution's experience with organ-preserving brachytherapy2
PO02472
PSA: Declining utilization of prostate brachytherapy2
PP08  Presentation Time: 10:40 AM2
How do you do it?: Gynecologic brachytherapy best practices at high volume institutions within the United States and Canada2
PO02332
Role of the gel spacer in safely delivering whole pelvic radiation therapy without central shielding in computed tomography-based image-guided adaptive brachytherapy for uterine cervical cancer patien2
Comparing long-term sexual dysfunction across different uterine cancer treatment modalities2
Dosimetric comparison of stereotactic MR-guided radiation therapy (SMART) and HDR brachytherapy boost in cervical cancer2
Outcomes and comparison of dosimetric parameters between intracavitary (Fletcher) and combined intracavitary/interstitial (Utrecht) brachytherapy in locally advanced cervical cancer2
PL04  Presentation Time: 2:15 PM2
GSOR23  Presentation Time: 12:20 PM2
GSOR06 Presentation Time: 5:25 PM2
Haralick texture feature analysis for Monte Carlo dose distributions of permanent implant prostate brachytherapy2
PSOR4  Presentation Time: 11:45 AM2
PO1122
Author Index2
Actinium-225 Targeted Agents: Where Are We Now?2
PO02552
Improving plan quality in cervical brachytherapy using a simple knowledge-based prediction tool for OAR dose (D2cm3)2
GSOR09  Presentation Time: 12:40 PM2
Outcomes from a 3-fraction high-dose-rate brachytherapy regimen for patients with cervical cancer2
Surgically targeted radiation therapy versus stereotactic radiation therapy: A dosimetric comparison for brain metastasis resection cavities2
Clinical and dosimetric outcomes of a 3-fraction high-dose-rate brachytherapy boost for the treatment of locally advanced cervical cancer in a safety net hospital2
PO03102
PL03 Presentation Time: 2:00 PM2
Gastrointestinal and genitourinary toxicity following high dose rate vaginal cuff brachytherapy for endometrial cancer2
Brachytherapy for rectal and anal cancer: Where are we and current perspectives?2
GSOR20  Presentation Time: 12:05 PM2
Letter to the editor regarding “Reducing dose to rectum by placement of a rectum-emptying tube in cervical cancer patients treated with brachytherapy”2
PSOR06  Presentation Time: 12:25 PM2
MSOR7 Presentation Time: 5:30 PM2
Saturday, July 13, 202410:30 AM - 11:30 AM GPP01 Presentation Time: 10:30 AM2
PO052
PO01112
PO02292
GSOR12 Presentation Time: 5:55 PM2
PO02562
Systematic review of brachytherapy for symptom palliation2
PO04062
Ten-year treatment complication outcomes of radical prostatectomy vs external beam radiation vs brachytherapy for 1503 patients with intermediate risk prostate cancer2
Effects of a novel form of intraoperative radiation therapy on quality of life among patients with early-stage breast cancer2
Sigmoid dose accumulation and reporting for multifractionated brachytherapy for cervical cancer: Methodological development of sigmoid points through virtual endoscopic method2
Feasibility of internal-source tracking with C-arm CT/SPECT imaging with limited-angle projection data for online in vivo dose verification in brachytherapy: A Monte Carlo simulation study2
Masthead2
PL03  Presentation Time: 2:30 PM1
PO02631
PO1101
From patient to pioneer: The inspiring journey of Dr. Brian Moran1
MSOR10  Presentation Time: 5:30 PM1
Reducing dose to rectum by placement of a rectum-emptying tube in cervical cancer patients treated with brachytherapy1
Editorial Board1
MSOR3  Presentation Time: 4:55 PM1
PO111
Table of Contents1
Time-resolved QA and brachytherapy applicator commissioning: Towards the clinical implementation1
Mortality and postinterventional complications after ablative treatment of liver malignancies: A cohort study of 4374 patients1
Masthead1
Comparison of air kerma rate between the S7500 and S7600 xoft axxent sources1
The use of Monte Carlo simulation techniques in brachytherapy: A comprehensive literature review1
PPP06 Presentation Time: 11:15 AM1
GPP06  Presentation Time: 8:50 AM1
Saturday, July 13, 202411:30 AM - 12:30 PMPSOR01 Presentation Time: 11:30 AM1
PO1201
Table of Contents1
PO421
Prostate brachytherapy in cooperative group clinical trials: What is the best path forward in the radiosurgery era?1
PO02021
MSOR05  Presentation Time: 8:50 AM1
PO191
PO901
PO271
Computed tomography-guided partial-breast brachytherapy using implanted catheters as fiducial markers versus co-registered magnetic resonance imaging1
Masthead1
Interstitial brachytherapy for gynecologic malignancies: Complications, toxicities, and management1
MRI-guided brachytherapy for locally advanced cervical cancer: Program initiation, learning curve and dose delivery results in Kuopio University Hospital1
PO03091
PO181
BP04 Presentation Time: 4:27 PM1
GSOR12  Presentation Time: 12:55 PM1
Long-term outcomes after enucleation or plaque brachytherapy of choroidal melanomas touching the optic disc1
PO02401
PO01021
PO061
PO30  Presentation Time: 10:30 AM1
PO1021
Image-guided brachytherapy following external-beam radiation therapy for patients with inoperable endometrial cancer1
PP05  Presentation Time: 4:06 PM1
Preoperative high-dose-rate brachytherapy for high-risk early-stage cervical cancer: Long-term clinical outcome analysis1
Prostate Posters PO04011
Permanent interstitial brachytherapy for prostate cancer implementing neoadjuvant prostatic artery embolization1
0.17397594451904